Addex Therapeutics Reports Critical Going Concern Warning, Low Cash, and Material Internal Control Weakness in Annual Report
ADXN sits 26% above its 52-week low of $5.41 on light trading volume (0.1× avg).
Summary
Addex Therapeutics' annual report reveals a substantial doubt about its ability to continue as a going concern beyond mid-June 2026, driven by a significant net loss and critically low cash reserves, compounded by a material weakness in internal financial controls.
Key Events · Earnings and Guidance · ADXN
-
Going Concern Warning Issued
Independent auditors issued a going concern warning, stating that existing cash and cash equivalents are only sufficient to fund operations through mid-June 2026, raising substantial doubt about the company's future viability.
-
Significant Net Loss and Critically Low Cash
The company reported a net loss of CHF 6.7 million for the fiscal year 2025 and a critically low cash balance of CHF 1.6 million as of December 31, 2025.
-
Material Weakness in Internal Controls
Management concluded that internal control over financial reporting was not effective as of December 31, 2025, due to a material weakness identified during the preparation of financial statements.
-
Major Partnership Terminated
Janssen Pharmaceuticals terminated the ADX71149 development program and returned all related intellectual property to Addex on April 17, 2025.
Analysis · ADXN · Life Sciences
This annual report presents a dire financial outlook for Addex Therapeutics. The explicit "going concern" warning from the independent auditor, coupled with a very limited cash runway of just over a month, indicates an urgent need for significant capital. The substantial net loss for the year further highlights the company's cash burn. The termination of the Janssen partnership for ADX71149 removes a key development program and potential future revenue stream. Furthermore, the disclosure of a material weakness in internal financial controls is a serious governance issue that can erode investor confidence and complicate future financing efforts. While the company has initiated a new collaboration and restarted an ATM program, these are unlikely to fully offset the immediate and severe financial challenges.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADXN was trading at $6.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $5.41 to $12.05. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.